Literature DB >> 17072981

Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Panthip Rattanasinganchan1, Kawin Leelawat, Sa-ard Treepongkaruna, Chintana Tocharoentanaphol, Somboon Subwongcharoen, Tuangporn Suthiphongchai, Rutaiwan Tohtong.   

Abstract

AIM: To establish and characterize a new cell line derived from peripheral cholangiocarcinoma of a Thai patient.
METHODS: The peripheral cholangiocarcinoma specimen surgically obtained from the patient was aseptically processed by washing and mincing before culturing in Ham's F12 medium containing 10% fetal bovine serum. After 3 mo, when the cell line has become homogeneous and stabilized, several features were investigated, including growth characteristics, immunofluorescence staining for cytokeratins, expression of tumor markers, chromosomal analysis by G-banding and multicolour fluorescence in situ hybridization (mFISH), in vitro migration and invasion characteristics.
RESULTS: The RMCCA-1 cell line has been established. These cells proliferated as a monolayer with a population doubling time of 48 h. Immunofluorescence staining showed positive staining for human cytokeratin 7 and 19 verifying the biliary epithelial origin. RMCCA-1 secreted carbohydrate antigen 19-9 (CA19-9), but insignificant levels of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). Chromosome analysis identified aneuploidy karyotypes with a modal chromosome number of 59. RMCCA-1 exhibited a low level of in vitro invasiveness, but a high degree of motility. The cell line exhibited a significant number of chromosomal aberrations as shown by mFISH and G-banding methods.
CONCLUSION: A new cell line derived from peripheral cholangiocarcinoma of a Thai patient has been established. This cell line shows a low level of in vitro invasiveness, but a high degree of motility. It will serve as a valuable tool for further studies on tumor biology, molecular pathogenesis, metastatic mechanism and response to therapeutic drugs of cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072981      PMCID: PMC4100638          DOI: 10.3748/wjg.v12.i40.6500

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.

Authors:  P H Quax; A C de Bart; J A Schalken; J H Verheijen
Journal:  Prostate       Date:  1997-08-01       Impact factor: 4.104

Review 2.  The role of chemotherapy in cholangiocarcinoma.

Authors:  S Thongprasert
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

3.  Characterization of a new rat cell line established from 2'AAF-induced combined hepatocellular cholangiocellular carcinoma.

Authors:  R Gil-Benso; A Martinez-Lorente; A Pellin-Perez; S Navarro-Fos; M A Gregori-Romero; C Carda; R Callaghan; A Peydro-Olaya; A Llombart-Bosch
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-01       Impact factor: 2.416

4.  Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding.

Authors:  D G Kim; S Y Park; K R You; G B Lee; H Kim; W S Moon; Y H Chun; S H Park
Journal:  Genes Chromosomes Cancer       Date:  2001-01       Impact factor: 5.006

5.  Anti-metastatic effects of curcusone B, a diterpene from Jatropha curcas.

Authors:  Surin Muangman; Montri Thippornwong; Rutaiwan Tohtong
Journal:  In Vivo       Date:  2005 Jan-Feb       Impact factor: 2.155

6.  High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.

Authors:  M Watanabe; M Chigusa; H Takahashi; J Nakamura; H Tanaka; T Ohno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

7.  Cancer control in Thailand.

Authors:  Vanchai Vatanasapt; Supannee Sriamporn; Patravoot Vatanasapt
Journal:  Jpn J Clin Oncol       Date:  2002-03       Impact factor: 3.019

8.  Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).

Authors:  Banchob Sripa; Saman Leungwattanawanit; Takayuki Nitta; Chaisiri Wongkham; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Chongrak Sripa; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

Review 9.  Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.

Authors:  Alphonse E Sirica
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

10.  The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.

Authors:  J R MacDougall; M R Bani; Y Lin; J Rak; R S Kerbel
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

View more
  24 in total

1.  Strong expression of CD133 is associated with increased cholangiocarcinoma progression.

Authors:  Kawin Leelawat; Taweesak Thongtawee; Siriluck Narong; Somboon Subwongcharoen; Sa-ad Treepongkaruna
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation.

Authors:  Chalinee Nuntagowat; Kawin Leelawat; Rutaiwan Tohtong
Journal:  Clin Exp Metastasis       Date:  2010-04-07       Impact factor: 5.150

3.  Molecular mechanisms of cholangiocarcinoma cell inhibition by medicinal plants.

Authors:  Surang Leelawat; Kawin Leelawat
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

4.  Prognostic relevance of circulating CK19 mRNA in advanced malignant biliary tract diseases.

Authors:  Kawin Leelawat; Siriluck Narong; Wandee Udomchaiprasertkul; Jerasak Wannaprasert; Sa-ard Treepongkaruna; Somboon Subwongcharoen; Tawee Ratanashu-ek
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

Review 5.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

6.  Basic fibroblast growth factor induces cholangiocarcinoma cell migration via activation of the MEK1/2 pathway.

Authors:  Siriluck Narong; Kawin Leelawat
Journal:  Oncol Lett       Date:  2011-06-29       Impact factor: 2.967

7.  Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.

Authors:  Thanpisit Lomphithak; Perawatt Akara-Amornthum; Keigo Murakami; Masatoshi Hashimoto; Hajime Usubuchi; Erina Iwabuchi; Michiaki Unno; Zhenyu Cai; Hironobu Sasano; Siriporn Jitkaew
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

8.  Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient.

Authors:  Banchob Sripa; Wunchana Seubwai; Kulthida Vaeteewoottacharn; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Worasak Kaewkong; Kanha Muisuk; Paweena Dana; Chatchai Phoomak; Worachart Lert-Itthiporn; Vor Luvira; Chawalit Pairojkul; Bin T Teh; Sopit Wongkham; Seiji Okada; Yaovalux Chamgramol
Journal:  Hum Cell       Date:  2020-03-23       Impact factor: 4.174

Review 9.  Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.

Authors:  Xinjun Lu; Panagiotis Paliogiannis; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2020-12-03       Impact factor: 17.425

10.  An animal model of buccal mucosa cancer and cervical lymph node metastasis induced by U14 squamous cell carcinoma cells.

Authors:  Xin Zhao; Liang Pang; Yu Qian; Qiang Wang; Yong Li; Mingyi Wu; Zilan Ouyang; Zhi Gao; Lihua Qiu
Journal:  Exp Ther Med       Date:  2013-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.